Anika reports incentive grants under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Sept. 9, 2024 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (NASDAQ: ANIK), a global early intervention orthopedic joint preservation company, today announced that on September 3, 2024, Anika granted a newly hired non-executive employee non-statutory stock options (“Options”) totaling 2,500 shares of common stock at an exercise price of $25.15 per share, representing the closing price of the common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the Compensation Committee of the Board of Directors pursuant to a delegation of authority by the Board of Directors, and served as a material inducement for the grantee to accept employment with Anika as part of his or her compensation for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

One third of the shares covered by the options will vest on each of the first three anniversaries of the grant date, and in any case for as long as the beneficiary continues to work for Anika continuously until the respective vesting date.